Therapeutic Targeting of RIG-I and MDA5 Might Not Lead to the Same Rome

RNA-based agonists targeting RIG-I or MDA5 are at the center of an ongoing hunt for novel pan-antivirals, vaccine adjuvants, and antitumor strategies